Vivos Therapeutics, Inc.
VVOS
$0.53
-$0.05-7.87%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 33.77% | 16.05% | 18.76% | 2.65% | 9.47% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 33.77% | 16.05% | 18.76% | 2.65% | 9.47% |
| Cost of Revenue | 23.80% | 14.75% | 37.59% | 13.33% | 9.92% |
| Gross Profit | 40.78% | 16.91% | 7.12% | -4.44% | 9.15% |
| SG&A Expenses | 71.67% | 48.57% | 19.31% | 0.86% | -17.42% |
| Depreciation & Amortization | 159.15% | 125.30% | 72.53% | 31.02% | 3.20% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 62.59% | 42.51% | 24.22% | 4.04% | -11.91% |
| Operating Income | -99.88% | -78.11% | -30.59% | -5.48% | 29.67% |
| Income Before Tax | -123.53% | -90.65% | -36.09% | -18.89% | 28.17% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -123.53% | -90.65% | -36.09% | -18.89% | 28.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -122.38% | -90.11% | -36.09% | -18.89% | 28.17% |
| EBIT | -99.88% | -78.11% | -30.59% | -5.48% | 29.67% |
| EBITDA | -96.48% | -75.53% | -28.53% | -4.31% | 30.94% |
| EPS Basic | -15.84% | 32.04% | 66.49% | 74.38% | 83.32% |
| Normalized Basic EPS | -15.51% | 32.13% | 66.49% | 74.37% | 83.32% |
| EPS Diluted | -15.84% | 32.04% | 66.49% | 74.38% | 83.32% |
| Normalized Diluted EPS | -15.51% | 32.13% | 66.49% | 74.37% | 83.32% |
| Average Basic Shares Outstanding | 83.50% | 111.86% | 164.37% | 286.71% | 319.30% |
| Average Diluted Shares Outstanding | 83.50% | 111.86% | 164.37% | 286.71% | 319.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |